The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Size Of The Cancer Clinical Decision Tools Market Progress Through 2030?
The cancer clinical decision tools market has seen substantial growth recently. This market is anticipated to expand from $0.55 billion in 2025 to $0.6 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.0%. Historically, this expansion can be ascribed to factors such as rising cancer incidence rates, the growing burden placed on primary care physicians, a scarcity of early diagnostic tools within primary care, a heightened emphasis on the accuracy of referrals, and the broader expansion of hospital and clinic infrastructure.
The market for cancer clinical decision tools is projected to experience substantial expansion over the coming years. This market is anticipated to reach $0.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. Several factors contribute to this growth during the forecast period, including advancements in AI-driven decision tools, the integration of genomic and risk profiling information, the proliferation of digital health platforms, a rise in government-led screening programs, and the increasing uptake of evidence-based oncology guidelines. Key trends characterizing this period involve a greater acceptance of clinical decision support tools within oncology, an enhanced emphasis on early cancer identification and risk categorization, a surge in general practitioners utilizing symptom checkers and risk calculators, the broadening of referral and decision frameworks guided by established guidelines, and the incorporation of cancer decision tools into primary care procedures.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3463&type=smp
Which Growth Factors Are Strengthening The Cancer Clinical Decision Tools Market Landscape?
The anticipated increase in cancer cases is projected to fuel the expansion of the cancer clinical decision tools market. Cancer incidence refers to the count of new cancer diagnoses within a particular demographic over a specific timeframe, indicating its frequency. This rise in incidence is attributed to heightened exposure to various risk factors, such as detrimental lifestyles, which can progressively result in genetic mutations and irregular cell proliferation. Cancer clinical decision tools are instrumental in monitoring, forecasting, and handling cancer cases more efficiently, facilitating early identification and prompt treatment that can influence observed cancer incidence patterns. For instance, in October 2025, NHS England, a UK-based publicly funded healthcare system, noted 354,820 new cancer diagnoses in 2023, representing an increase of 8,605 compared to 2022. Consequently, the worldwide escalation in cancer incidence rates is expected to elevate the demand within the cancer clinical decision tools market.
Which Segment Groups Define The Cancer Clinical Decision Tools Market Landscape?
The cancer clinical decision tools market covered in this report is segmented –
1) By Type: Risk Assessment Tool(RAT), Qcancer
2) By End-User: Hospital, Clinics
Subsegments:
1) By Risk Assessment Tool (RAT): Family History Assessment, Genetic Testing and Counseling, Lifestyle and Environmental Risk Factors Evaluation
2) By Qcancer: Symptom Checker, Risk Calculator, Guideline-Based Recommendations
What Trends Are Affecting The Growth Of The Cancer Clinical Decision Tools Market?
Companies engaged in the cancer clinical decision tools market are increasingly adopting AI-powered prognostic decision support systems to address the growing demand for more tailored, data-driven oncology care. This demand is fueled by rising cancer incidence, the necessity for improved risk stratification, and the pressure to streamline treatment pathways. These AI prognostic systems utilize deep-learning models to analyze various data types, including imaging, electronic health records, and clinical biomarkers, to predict outcomes such as survival, recurrence risk, or treatment response with significantly greater accuracy than conventional rule-based tools. As an illustration, in February 2025, Onc.AI, a US-based health-tech company, received FDA Breakthrough Device Designation for its Serial CTRS (Cancer Treatment Risk Stratification) tool; this AI tool differentiates non–small cell lung cancer (NSCLC) patients into high- and low-risk mortality categories by processing diagnostic imaging scans with a deep-learning algorithm, thereby empowering oncologists to make more well-informed decisions concerning therapy intensity and follow-up. Serial CTRS’s capability to predict long-term survival outcomes facilitates better patient grouping, more personalized treatment planning, and optimized resource allocation, representing a significant progression from standard prognostic models that rely on restricted clinical parameters.
Who Are The Businesses Driving Activity In The Cancer Clinical Decision Tools Market?
Major companies operating in the cancer clinical decision tools market are McKesson Corporation, Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., National Decision Support Company, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc.
Access The Complete Cancer Clinical Decision Tools Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Which Region Stands As The Largest Contributor To The Cancer Clinical Decision Tools Market?
North America was the largest region in the cancer clinical decision tools market in 2025. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Cancer Clinical Decision Tools Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3463&type=smp
Browse Through More Reports Similar to the Global Cancer Clinical Decision Tools Market 2026, By The Business Research Company
Polymerase Chain Reactions Devices Reagents And Uses Market Report 2026
Cardiovascular Monitoring And Diagnostic Devices And Equipment Market Report 2026
Veterinary Diagnostic Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model